Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 659 first isolates · URO · Febrile UTI / pyelonephritis · 2024-07-14 → 2025-07-13
UrologyNarrowest option reaching 80 % coverage, no active warning
meropenem 84 % (81 %–87 %)
Carbapenem: reserve for ESBL / critically ill patients.
Not covered: Enterococcus faecalis (10 %), Staphylococcus aureus (3 %), Staphylococcus saprophyticus (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
ciprofloxacin CIP
trend · Escherichia coli ⚠ Escherichia coli: 46 % resistant in the last 4 weeks (baseline 12 %)
73 %
55 %
n = 66
ceftriaxone CRO
trend · Escherichia coli ⚠ Active ESBL cluster (19 cases)
⚠ Escherichia coli: 46 % resistant in the last 4 weeks (baseline 7 %)
72 %
53 %
n = 66
cefuroxime CXM
trend · Escherichia coli ⚠ Active ESBL cluster (19 cases)
⚠ Escherichia coli: 51 % resistant in the last 4 weeks (baseline 15 %)
65 %
47 %
n = 66
Most likely organisms for this profile
Escherichia coli
58 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
5 %
Pseudomonas aeruginosa
4 %
Staphylococcus aureus
3 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.